A review of dextromethorphan and bupropion (Auvelity™) for the treatment of agitation in Alzheimer's disease.

Authors

Rajesh R Tampi, Kayla Murphy, Julia Golden, Haley Schuster, Robin Conyers

Published in

Drugs in context. Volume 15. Epub Oct 07, 2026.

Abstract

Dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets (Auvelity^TM) became the second medication to be approved by the FDA for the treatment of agitation in Alzheimer's disease dementia after brexpiprazole. It also became the first non-antipsychotic medication to be approved for this specific indication. In this Editorial, the available data regarding the efficacy and adverse effects of this medication in the treatment of agitation in Alzheimer's disease dementia are reviewed.

PMID:
42891424
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.